Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Join Channel
Consolidated Standalone

Kopran

₹239.3 -2.3 | 1%

Market Cap ₹1154 Cr.

Stock P/E 28.6

P/B 2.5

Current Price ₹239.3

Book Value ₹ 94.8

Face Value 10

52W High ₹292.4

Dividend Yield 1.25%

52W Low ₹ 140

Edit Ratio

Kopran Research see more...

Overview Inc. Year: 1958Industry: Pharmaceuticals & Drugs

Kopran Ltd is engaged in pharmaceutical business. The Company's commercial enterprise units consist of Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare. It gives its merchandise in healing categories, together with anthelmintic, anti-allergic, antibiotic, cardiovascular, diabetic, gastroenterology, ache and antipyretic, and ache management, among others. The Company's bulk drugs encompass Atenolol, Amlodipine Besylate, Metoprolol Succinate, Metoprolol Tartrate, Ceftriaxone Sodium Sterile, Doripenem, Tebipenem, Roxithromycin, Rivaroxaban, Zolmitriptan, Azithromycin, Pregabalin, Lymecycline and Nitroxoline. In addition, it gives oral care, lifestyle, beauty and customized hygiene products. Its manufacturing facility is located at Khopoli, Raigad District, Maharashtra. The Company's subsidiaries consist of Kopran Research Laboratories Ltd, Kopran (H.K) Ltd and Kopran Lifesciences Ltd.

Read More..

Kopran Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Kopran Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 128 132 143 126 117 158 149 117 153 159
Other Income 3 4 2 1 0 2 4 2 0 2
Total Income 130 136 145 126 117 160 153 119 153 161
Total Expenditure 104 105 117 112 107 146 137 111 130 135
Operating Profit 27 31 28 14 11 15 16 9 23 26
Interest 1 2 1 1 1 2 2 2 2 2
Depreciation 3 3 3 3 3 3 3 3 3 3
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 23 27 24 10 6 9 11 4 18 21
Provision for Tax 6 7 7 2 1 2 3 1 4 5
Profit After Tax 17 20 18 8 5 7 8 3 14 16
Adjustments -0 0 0 0 -0 -0 -0 0 0 0
Profit After Adjustments 17 20 18 8 5 7 8 3 14 16
Adjusted Earnings Per Share 4 4.6 3.6 1.6 1 1.4 1.7 0.6 2.9 3.3

Kopran Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 250 303 326 296 310 313 358 359 492 478 551 578
Other Income 2 2 7 2 11 11 4 1 18 11 3 8
Total Income 252 305 332 299 320 324 362 360 510 488 554 586
Total Expenditure 217 260 294 266 274 284 312 313 410 390 499 513
Operating Profit 35 45 38 33 47 40 49 47 100 98 55 74
Interest 12 14 13 13 14 9 9 9 6 5 6 8
Depreciation 12 13 10 8 8 9 9 10 10 11 13 12
Exceptional Income / Expenses 0 0 -54 -1 0 0 0 -1 0 0 0 0
Profit Before Tax 11 17 -39 11 25 23 32 28 83 82 36 54
Provision for Tax 0 0 0 0 5 2 8 7 22 21 9 13
Profit After Tax 11 17 -39 11 20 20 24 21 62 61 27 41
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 11 17 -39 11 20 20 24 21 62 61 27 41
Adjusted Earnings Per Share 2.8 4.4 -9.5 2.5 4.6 4.7 5.6 4.9 14.2 12.7 5.6 8.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 15% 15% 12% 8%
Operating Profit CAGR -44% 5% 7% 5%
PAT CAGR -56% 9% 6% 9%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 60% 5% 44% 22%
ROE Average 6% 18% 16% 10%
ROCE Average 8% 20% 18% 14%

Kopran Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 97 115 99 109 125 145 168 190 245 426 439
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 69 63 14 29 32 30 41 32 21 19 18
Other Non-Current Liabilities 4 4 4 4 -0 2 5 9 12 14 16
Total Current Liabilities 93 117 158 122 136 136 135 140 161 152 177
Total Liabilities 263 299 275 264 293 312 349 370 439 611 650
Fixed Assets 109 105 102 101 104 104 113 111 112 151 165
Other Non-Current Assets 32 34 4 9 9 14 29 36 50 45 86
Total Current Assets 123 160 170 154 180 193 208 223 277 415 399
Total Assets 263 299 275 264 293 312 349 370 439 611 650

Kopran Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 7 1 1 1 1 1 0 0 1 1 6
Cash Flow from Operating Activities 15 3 46 29 16 26 25 31 60 -33 34
Cash Flow from Investing Activities -9 -9 -10 -9 -18 -11 -25 -13 -25 -84 -13
Cash Flow from Financing Activities -12 7 -37 -19 2 -15 -1 -18 -35 123 -20
Net Cash Inflow / Outflow -7 0 -0 0 -0 -0 -0 0 0 5 2
Closing Cash & Cash Equivalent 1 1 1 1 1 0 0 1 1 6 7

Kopran Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 2.85 4.4 -9.52 2.48 4.6 4.74 5.55 4.86 14.24 12.66 5.65
CEPS(Rs) 6.04 7.71 -7.17 4.36 6.53 6.71 7.58 7.07 16.6 14.96 8.29
DPS(Rs) 0 0 0 0 0 0 0 0 1.5 3 3
Book NAV/Share(Rs) 22.7 27.14 18.43 23.15 28.83 33.46 38.95 43.86 56.65 88.4 91.11
Core EBITDA Margin(%) 13.08 13.65 9.39 9.9 11.34 9.23 12.69 12.92 16.29 18 9.28
EBIT Margin(%) 8.94 10.14 -7.81 7.63 12.07 10 11.36 10.29 17.87 17.93 7.55
Pre Tax Margin(%) 4.32 5.5 -11.69 3.51 7.77 7.27 8.85 7.82 16.63 16.88 6.46
PAT Margin (%) 4.32 5.5 -11.69 3.51 6.25 6.51 6.71 5.81 12.29 12.6 4.88
Cash Profit Margin (%) 9.16 9.64 -8.81 6.17 8.86 9.21 9.15 8.46 14.33 14.89 7.16
ROA(%) 4.33 6.11 -13.63 3.98 7.15 6.77 7.27 5.84 15.22 11.62 4.32
ROE(%) 13.39 17.65 -43.06 12.19 17.71 15.21 15.34 11.74 28.34 18.19 6.29
ROCE(%) 11.81 14.27 -12.48 13.09 19.24 13.88 16.3 13.69 30.4 21.4 8.3
Receivable days 63.96 62.68 74.79 82.54 74.44 79.96 77.21 90.59 77.53 93.2 94.82
Inventory Days 50.98 52.48 53.6 62.26 68.37 76.3 73.66 81.75 68.65 94.14 91.76
Payable days 114.22 87.63 98.57 138.03 115.29 114.47 106.92 100.26 90.6 108.83 81.67
PER(x) 4.61 4.85 0 19.77 16.5 11.64 7.49 5.22 7.37 22.24 19.55
Price/Book(x) 0.58 0.79 2.47 2.12 2.63 1.65 1.07 0.58 1.85 3.19 1.21
Dividend Yield(%) 0 0 0 0 0 0 0 0 1.43 1.07 2.72
EV/Net Sales(x) 0.64 0.71 0.83 0.97 1.35 1.03 0.76 0.54 1.04 2.88 1.08
EV/Core EBITDA(x) 4.48 4.85 7.09 8.8 8.91 8.03 5.52 4.08 5.15 14.03 10.85
Net Sales Growth(%) 25.8 21.03 7.55 -9.03 4.52 1.16 14.23 0.45 36.81 -2.91 15.38
EBIT Growth(%) 53.28 37.57 -182.67 189.01 65.22 -18.15 29.14 -8.51 140.82 -2.99 -51.5
PAT Growth(%) 108.22 54.5 -327.76 127.4 85.77 2.89 17.26 -12.5 193.08 -0.93 -55.38
EPS Growth(%) 108.22 54.5 -316.4 126.03 85.77 2.89 17.26 -12.5 193.07 -11.13 -55.38
Debt/Equity(x) 1.06 1.12 0.92 0.65 0.76 0.61 0.58 0.47 0.27 0.17 0.17
Current Ratio(x) 1.32 1.36 1.07 1.26 1.32 1.43 1.54 1.59 1.72 2.74 2.25
Quick Ratio(x) 0.93 0.91 0.79 0.78 0.87 0.9 1 0.96 1.1 1.75 1.52
Interest Cover(x) 1.94 2.19 -2.02 1.85 2.81 3.66 4.52 4.17 14.36 16.98 6.93
Total Debt/Mcap(x) 2.01 1.54 0.41 0.34 0.29 0.37 0.54 0.81 0.15 0.05 0.14

Kopran Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 43.78 44.25 44.25 44.25 44.3 44.3 44.49 44.49 44.49 44.49
FII 0.75 0.53 0.5 0.51 0.34 0.41 0.34 0.39 0.48 0.84
DII 0.16 0.14 0.14 0.14 0.14 0.14 0.14 0.35 0.14 1.2
Public 55.31 55.07 55.11 55.1 55.22 55.15 55.03 54.77 54.89 53.47
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 108.83 to 81.67days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 44.49%.
  • The company has delivered a poor profit growth of 6% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Kopran News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!